Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two agents: - **Epigallocatechin-3-gallate (EGCG)** is the main polyphenol in green tea, known for its antioxidant, anti-inflammatory, and neuroprotective properties. It acts by scavenging reactive oxygen species and modulating signaling pathways involved in inflammation and neuronal survival[6][10]. EGCG has been studied as a neuroprotectant in various neurological diseases. - **Glatiramer acetate** is an immunomodulatory drug approved for the treatment of relapsing forms of multiple sclerosis (MS). It consists of synthetic polypeptides that mimic myelin basic protein and modulate immune responses by shifting T-cell populations from pro-inflammatory to anti-inflammatory phenotypes[7][9]. The combination has been investigated primarily for multiple sclerosis. Preclinical studies suggest synergistic effects on neuroprotection and immunomodulation—combining EGCG’s neuroregenerative actions with glatiramer acetate’s immune-modifying properties[1][2]. However, clinical trials have not demonstrated significant additional benefit over standard therapy with glatiramer acetate alone in MS patients[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on epigallocatechin-3-gallate + glatiramer acetate.